The concept according to which unique, rare and common sequences may define immunogenicity,
immunopathogenicity and immunotolerance, respectively, is graphically illustrated using a melanoma-associatedantigen,
Melan-A/Mart-1, as a model. The final picture is consolidated by experimentally validated data from the
scientific literature and may represent a concrete prelude to effective immunotherapies exempt from collateral
Keywords: Anti-cancer immunotherapy, autoimmunity, melan-A/Mart-1, immunogenicity, immunopathogenicity,
immunotolerance, sequence similarity, the low-similarity theory.
Rights & PermissionsPrintExport